An article on Triad Therapeutics Inc. in the Dec. 11, 2002, issue of BioWorld Today should have said the company expects to file an investigational new drug application in mid-2004 for an antibiotic (not antibody) candidate. Also, a company official should have been quoted as saying the goal is to develop molecules that bind tightly and with high "affinity" and specificity to the partner's target.

Editor's note: The correction has been made in BioWorld Online.